ADVFN Logo

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

ALZN Alzamend Neuro Inc

1.00
-0.02 (-1.96%)
Mar 28 2024 - Closed
Delayed by 15 minutes

Period:

Draw Mode:

Volume 16,662
Bid Price 0.94
Ask Price 1.08
News -
Day High 1.04

Low
0.74

52 Week Range

High
11.91

Day Low 0.98
Share Name Share Symbol Market Stock Type
Alzamend Neuro Inc ALZN NASDAQ Common Stock
  Price Change Price Change % Share Price Last Trade
-0.02 -1.96% 1.00 19:00:00
Open Price Low Price High Price Close Price Previous Close
0.98 0.98 1.04 1.00 1.02
Trades Shares Traded VWAP Financial Volume Average Volume 52 Week Range
120 16,662 US$ 1.00 US$ 16,716 - 0.74 - 11.91
Last Trade Type Quantity Price Currency
18:49:44 6 US$ 1.02 USD

Alzamend Neuro Inc Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
7.26M 7.12M - 0 -14.88M -2.09 -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- - - -

more financials information »

Alzamend Neuro News

Date Time Source News Article
3/07/202415:30Edgar (US Regulatory)Form 8-K - Current report
2/02/202415:30Edgar (US Regulatory)Form 8-K - Current report
1/05/202415:30Edgar (US Regulatory)Form 8-K - Current report
12/15/202315:30Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]
12/11/202307:00Business WireAlzamend Neuro Receives FDA “Study May Proceed” Notification..
11/20/202307:00Business WireAlzamend Neuro Receives FDA “Study May Proceed” Notification..
11/16/202315:30Edgar (US Regulatory)Form 8-K - Current report
11/16/202307:00Business WireAlzamend Neuro Regains Compliance with Nasdaq’s Minimum Bid..
11/13/202307:00Business WireAlzamend Neuro Submits IND Application for a Phase IIA..
10/30/202315:30Edgar (US Regulatory)Form 8-K - Current report
10/30/202307:00Business WireAlzamend Neuro Announces Reverse Stock Split
10/23/202307:00Business WireAlzamend Neuro Submits IND Application for a Phase IIA..
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No ALZN Message Board. Create One! See More Posts on ALZN Message Board See More Message Board Posts

Historical ALZN Price Data

Period † Open High Low VWAP Avg. Daily Vol Change %
1 Week1.041.10170.9536011.0240,237-0.04-3.85%
1 Month0.941.290.90011.10103,9190.066.38%
3 Months0.941.290.741.0453,3070.066.38%
6 Months3.5163.8970.741.78140,326-2.52-71.56%
1 Year6.7511.910.744.65160,393-5.75-85.19%
3 Years435.00503.250.7442.031,251,216-434.00-99.77%
5 Years435.00503.250.7442.031,251,216-434.00-99.77%

Alzamend Neuro Description

Alzamend Neuro Inc is an early clinical stage biopharmaceutical company. It is focused on developing novel products for the treatment of neurodegenerative diseases and psychiatric disorders, including Alzheimer's. Its mission is to develop and market safe and effective treatments. The company's pipeline consists of two novel therapeutic drug candidates, AL001 - a patented ionic cocrystal technology delivering lithium via a therapeutic combination of lithium, proline and salicylate, and AL002 - a patented method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine that seeks to restore the ability of a patient's immunological system to combat Alzheimer's.

Your Recent History

Delayed Upgrade Clock